Hiroyuki Harada

Hiroyuki Harada

Auto-generated profile, based on publicly available information

Hiroyuki Harada

Department of Oral and Maxillofacial Surgical Oncology, Division of Oral Health Sciences, Graduate School of Medical and Dental Sciences, Institute of Science Tokyo, Tokyo 113-8510, Japan

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 November 2019 in Cancer Science
Verified
Journal Article
Open access
PDF file
DYDaisuke Yamamoto
Daisuke Yamamoto
KKKou Kayamori
Kou Kayamori
KSKei Sakamoto
Kei Sakamoto
MTMaiko Tsuchiya
Maiko Tsuchiya
TITohru Ikeda
Tohru Ikeda
MHMiki Hara‐Yokoyama
Miki Hara‐Yokoyama
Claudins are the major component of tight junctions, which form a primary barrier to paracellular diffusion and maintain cell polarity in normal epithelia and endothelia. In cancer cells, claudins play additional roles besides serving as components of the tight junctions, and participate in anoikis or invasion. Among the claudin family proteins, claudin‐1 has the most promising potential, both diagnostically and prognostically, in many types of cancers, including oral, gastric, liver, and colon cancers. However, conflicting results have been reported in relation to the degree of claudin‐1 expression and the prognosis, suggesting that the expression level of claudin‐1 alone is not sufficient to analyze the relationship between claudin‐1 and cancer progression. As endocytic trafficking of claudin‐1 has been reported in several epithelial cell types in vitro, we aimed to determine whether intracellular localization of claudin‐1 is the missing aspect between claudin‐1 and cancer. We investigated the expression of claudin‐1 in 83 tongue squamous cell carcinoma (TSCC) pathological specimens. Although the expression level of claudin‐1 based on immunohistochemistry was not associated with TSCC progression, within the high claudin‐1 expression group, the incidence of intracellular localization of claudin‐1 was correlated with cervical lymph node metastasis. In an in vitro experiment, claudin‐1 was constitutively internalized in TSCC‐derived cells. Motility of TSCC‐derived cells was increased by deficiency of claudin‐1, suggesting that the decrease in cell‐surface claudin‐1 promoted the cell migration. Therefore, intracellular localization of claudin‐1 at the invasion front may represent a promising diagnostic marker of TSCC.

1 October 2021 in Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
Verified
Journal Article
Closed access
ESEri Shibata
Eri Shibata
KMKei-Ichi Morita
Kei-Ichi Morita
KKKou Kayamori
Kou Kayamori
STShoichiro Tange
Shoichiro Tange
HSHiroki Shibata
Hiroki Shibata
TYTetsuya Yoda
Tetsuya Yoda

1 December 2021 in Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology
Verified
Journal Article
Closed access
HSHiroaki Shimono
Hiroaki Shimono
HHHideaki Hirai
Hideaki Hirai
YOYu Oikawa
Yu Oikawa
YMYumi Mochizuki
Yumi Mochizuki
TKTakeshi Kuroshima
Takeshi Kuroshima
HHHiroyuki Harada
Hiroyuki Harada

1 January 2020 in Experimental Cell Research
Verified
Journal Article
Closed access
HNHitomi Nojima
Hitomi Nojima
HHHisao Homma
Hisao Homma
YOYusuke Onozato
Yusuke Onozato
KAKaida Atsushi
Kaida Atsushi
HHHiroyuki Harada
Hiroyuki Harada
MMMasahiko Miura
Masahiko Miura

15 December 2011 in ISRN Dentistry
Verified
Journal Article
Open access
PDF file
TYToru Yanagawa
Toru Yanagawa
AYAkira Yamaguchi
Akira Yamaguchi
HHHiroyuki Harada
Hiroyuki Harada
Kenji YamagataKenji Yamagata
Kenji Yamagata
NINaomi Ishibashi
Naomi Ishibashi
HBHiroki Bukawa
Hiroki Bukawa
Cheilitis glandularis (CG) is a rare disorder characterized by swelling of the lip with hyperplasia of the labial salivary glands. CG is most frequently encountered in the lower lip, in middle-aged to older Caucasian men; however Asian cases were rarely reported. In this paper we present two cases of CG in Asian-Japanese men. One was a 23-year-old male with CG of the superficial suppurative type. The other was a 54-year-old male with deep suppurative type. We also reviewed the Japanese cases of CG in the literature and discussed about clinical feature of Japanese CG.

14 December 2023 in Journal of Dental Sciences
Verified
Journal Article
Open access
MOMitsunobu Otsuru
Mitsunobu Otsuru
NYNobuhiro Yamakawa
Nobuhiro Yamakawa
TKTadaaki Kirita
Tadaaki Kirita
SYShin-ichi Yamada
Shin-ichi Yamada
HKHiroshi Kurita
Hiroshi Kurita
TYTomohiro Yamada
Tomohiro Yamada
For unresectable recurrent/metastatic head and neck cancer, pembrolizumab alone or pembrolizumab combined with cisplatin and 5-fluorouracil is the first-line therapy, depending on the PD-L1 combined positive score (CPS). However, this is based on clinical studies of head and neck cancer, and few similar studies have been conducted on oral cancer alone. This study aimed to investigate the current status of pharmacotherapy for unresectable, recurrent, or metastatic oral cancer. Patients with unresectable or recurrent/metastatic oral cancer who received cetuximab, nivolumab, or pembrolizumab as first-line treatment were reviewed. Overall survival (OS), progression-free survival (PFS), PFS 2 (PFS2), overall response rate (ORR), disease control rate (DCR), and immune-related adverse events were obtained from medical records. A total of 155 patients were enrolled from six hospitals. The ORR in the nivolumab, pembrolizumab, and cetuximab groups was 17.2 %, 4.2 %, and 21.6 %, respectively, and the DCR was 37.9 %, 41.7 %, and 58.8 %, respectively. Median OS in nivolumab, pembrolizumab, and cetuximab groups was 10.3, 9.5, and 11.1 months, respectively. No significant differences were observed in survival among the three groups. The small number of cases and the retrospective nature of the study precluded the determination of the more effective first-line treatment among the three drugs. The current statuses of nivolumab, pembrolizumab, and cetuximab in unresectable recurrent metastatic oral cancer was reported.